Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;4(1):3-8.
doi: 10.4103/0973-6247.59384.

Leukoreduced blood components: Advantages and strategies for its implementation in developing countries

R R Sharma  1 , Neelam Marwaha
Affiliations

Leukoreduced blood components: Advantages and strategies for its implementation in developing countries

R R Sharma et al. Asian J Transfus Sci. 2010 Jan.

Abstract

Removal of leucocytes from various blood products has been shown to minimize Febrile nonhemolytic transfusion reactions, HLA alloimmunization, platelet refractoriness in multitransfused patients and prevention of transmission of leukotropic viruses such as EBV and CMV. Rapidly growing size of hemato-oncological patients in our country requiring multiple transfusion of blood and components during the course of their management pose a great challenge to transfusion services to provide them red cell and platelet antigen matched products in alloimmunized subjects. Thus removal of leucocytes below a certain threshold, </= 5 x 10(6) in a blood component certainly helps in prevention of alloimmunization and associated risks in these patients. Currently the best Leucoreduction can be achieved with the help of 3rd and 4th generation leukofilters, both in laboratory and patient bed side, and state of the art apheresis devices. The present article briefly reviews the current literature for pros and cons of leucofilteration and its scope of implementation in the cost constrained settings.

Keywords: Blood component; developing countries; leukoreduced component.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in with leukemia. Blood. 1983;62:815–20. - PubMed
    1. Sniecinski I, O' Donnel MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71:1402–7. - PubMed
    1. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. 1988;72:964–69. - PubMed
    1. van Marwijk Koov M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte -depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization < a prospective, randomized trial. Blood. 1991;77:201–5. - PubMed
    1. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of Prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reaction to platelet concentrates and RBC. Transfusion. 2004;44:10–5. - PubMed